Plasma-derived Therapy Market By Protein-derived (Immunoglobulin, Clotting factors, and Albumin), Application (Infectious diseases and Hereditary Diseases), and End User (Hospitals & Clinics and Research Institutes) – Analysis & Forecast 2020-2030

Report ID : 334  |  Published Date : Jul 2020  |  Pages : 160  |  Region : Global  |  Report Code : PH-22

Plasma-derived Therapy Market Overview and Introduction

Plasma is the transparent, straw-colored liquid portion of blood that remains after red blood cells (RBCs), white blood cells (WBCs), platelets, and other cellular components are separated. Plasma is a significant component of the blood and accounts for approximately 55% of the entire blood content. It constitutes of water, salts, enzymes, antibodies, and other proteins; and is separated from the blood by a process known as plasmapheresis. Further, protein such as immunoglobulin, clotting factors, and albumin are also derived from plasma.

Plasma-derived therapy replaces missing or deficient proteins and permits individuals to lead a healthy and more productive life. This therapy is used for the treatment of rare, life-threatening, chronic, and genetic diseases, such as immune deficiencies, pulmonary disorders, neurological disorders, shock & trauma, liver cirrhosis, and infectious diseases (tetanus, hepatitis, COVID-19 [still under clinical trials] and rabies), among others. 

The global plasma-derived therapy market is mainly driven by the growing use of immunoglobulins across various therapeutic areas and rising prevalence of life-threatening diseases such as immune deficiency diseases & hemophilia, among others. Furthermore, growing awareness regarding blood & plasma donation and increasing research & development activities, are also playing a pivotal role in contributing to the growth of the plasma-derived therapy market globally. However, the high cost of therapy and lack of reimbursement policies are likely to restrain the market to a certain extent.

The global plasma-derived therapy market has been analyzed from four perspectives, viz., Protein-derived, Application, End User, and Region.

Plasma-derived Therapy Market by Protein-derived

Based on protein derived, the market has been segmented into Immunoglobulin, Clotting Factors, Albumin, and Others. The immunoglobulin segment is expected to account for the highest share during the forecast period, owing to the benefits of these proteins when used for the treatment of various diseases. Immunoglobulins (which also function as antibodies) are utilized by the immune system of the body to neutralize pathogens such as bacteria and viruses. These immunoglobulins are derived from plasma of a recovered patient and are used to immunize patients suffering from various autoimmune, infectious, and idiopathic diseases.

Plasma-derived Therapy Market by Application

Based on application, the market has been segmented into Infectious Diseases, Hereditary Diseases and Others. Hereditary Diseases are expected to account for the highest share during the forecast period. Few of the hereditary diseases that are treated by plasma-derived therapy include hemophilia, primary immunodeficiency disorder (PID), hereditary angioedema, and Von Willebrand disease, among others. Whereas, infectious diseases treated by plasma-derived therapy include H1N1, COVID-19 (still under clinical trials), and hepatitis, among others. The growth of the hereditary diseases segment in the global market can largely be attributed to its high prevalence and growing awareness about treatment options provided by plasma-derived therapies.

Plasma-derived Therapy Market by End User

Based on end user, the market has been segmented into Hospitals & Clinics and Research Institutes. The hospitals & clinics segment is expected to dominate the plasma-derived therapy market with the highest share during the forecast period. The growth of the segment can be attributed to the frequent visits of patients to hospitals for diagnosis & treatment of various hematological & immunological disorders

Plasma-derived Therapy Market by Region

Based on the region, the global plasma-derived therapy market has been segmented into North America, Europe, Asia Pacific, and the Rest of the World (ROW). North America dominated the plasma-derived therapy market, followed by the Asia Pacific. The large share of North America in the global market can largely be attributed to the early approval of plasma-derived products and the growing use of immunoglobulins therapy across various therapeutic areas. For Instance, since the detection of the first case of COVID-19 in the US on January 19, 2020, the US FDA has ramped up medical countermeasures to treat and prevent the spread of COVID-19. The US government has collaborated with multiple non-government organizations and biotech companies to develop “hyper-immune” treatment products from convalescent plasma, to boost the immune response of infected patients. Furthermore, advanced healthcare infrastructure for storing and maintaining high-quality source plasma has played a crucial role in dictating the growth of this region in the global plasma-derived therapy market.

Plasma-derived Therapy Market Prominent Players

Some of the prominent players operating in the plasma-derived therapy market are Takeda Pharmaceutical Company Limited., Biotest AG, CSL Limited, Grifols, S.A., Kedrion S.p.A, LFB, Bio Products Laboratory USA., Inc., China Biologic Products Holdings, Inc., Octapharma AG, and Emergent BioSolutions Inc., among others.